Capital Royalty provides capital in the form of royalty bonds, traditional royalty purchases, and revenue interest transactions. The value of each transaction is based on the future cash flow streams from royalties on commercialized biopharmaceutical products and medical technologies.  

We invest in a broad range of healthcare market segments, including:

• Pharmaceuticals
• Biotechnology
• Drug delivery technologies
• Diagnostics
• Medical devices

Capital Royalty targets investments between $25 and $200 million and may work with co-investors to execute larger transactions. We focus on transactions involving FDA-approved healthcare products that are supported by companies with solid sales and marketing infrastructures.

We leverage our industry-leading structuring experience to customize each transaction to meet the financing needs of our business partners. As leaders in structuring royalty bonds and bond-like structures that allow royalty owners to borrow against their royalty streams as opposed to selling outright, we are uniquely aligned to work with owners of high-quality healthcare intellectual property assets.